Rafferty Asset Management
RLAY icon

Rafferty Asset Management’s Relay Therapeutics RLAY Stock Holding History

Rafferty Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.27M Buy
174,785
+24,167
+16% +$351K 0.01% 510
2026
Q1 		$1.5M Sell
150,618
-43,138
-22% -$386K 0.01% 668
2025
Q4 		$1.64M Buy
193,756
+42,181
+28% +$301K 0.01% 693
2025
Q3 		$791K Sell
151,575
-30,382
-17% -$116K ﹤0.01% 837
2025
Q2 		$630K Sell
181,957
-23,111
-11% -$68.7K ﹤0.01% 841
2025
Q1 		$537K Sell
205,068
-44,493
-18% -$174K ﹤0.01% 851
2024
Q4 		$1.03M Buy
249,561
+69,531
+39% +$378K ﹤0.01% 787
2024
Q3 		$1.27M Sell
180,030
-13,902
-7% -$104K ﹤0.01% 748
2024
Q2 		$1.26M Sell
193,932
-270,128
-58% -$1.85M ﹤0.01% 760
2024
Q1 		$3.85M Buy
464,060
+136,512
+42% +$1.33M 0.01% 524
2023
Q4 		$3.61M Sell
327,548
-50,197
-13% -$424K 0.02% 513
2023
Q3 		$3.18M Sell
377,745
-249,268
-40% -$2.68M 0.02% 489
2023
Q2 		$7.88M Buy
627,013
+183,387
+41% +$2.28M 0.04% 289
2023
Q1 		$7.31M Sell
443,626
-30,653
-6% -$550K 0.05% 275
2022
Q4 		$7.09M Buy
474,279
+278,160
+142% +$5.32M 0.06% 295
2022
Q3 		$4.39M Buy
196,119
+14,021
+8% +$308K 0.05% 357
2022
Q2 		$3.05M Buy
182,098
+11,824
+7% +$253K 0.03% 384
2022
Q1 		$5.1M Sell
170,274
-19,728
-10% -$479K 0.03% 389
2021
Q4 		$5.83M Buy
190,002
+92,906
+96% +$2.94M 0.03% 317
2021
Q3 		$3.06M Buy
97,096
+20,871
+27% +$703K 0.02% 469
2021
Q2 		$2.79M Sell
76,225
-8,584
-10% -$283K 0.02% 531
2021
Q1 		$2.93M Buy
84,809
+73,840
+673% +$3.2M 0.02% 509
2020
Q4 		$456K Buy
+10,969
New +$496K ﹤0.01% 701

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Rafferty Asset Management's RLAY Position: Q2 2026 in Review

Rafferty Asset Management increased its Relay Therapeutics (RLAY) stake by 16% in Q2 2026, buying an estimated $351K and bringing the position to 174,785 shares worth $3.27M. The position accounts for 0.01% of the portfolio, ranked #510.

Rafferty Asset Management first reported a position in RLAY in Q4 2020 and has held it in 23 quarters since. The position peaked at $7.88M in Q2 2023. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Rafferty Asset Management held 174,785 shares of Relay Therapeutics worth $3.27M as of Q2 2026.
  • Rafferty Asset Management bought 24,167 Relay Therapeutics shares in Q2 2026, an estimated $351K.
  • Relay Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #510 holding.
  • Rafferty Asset Management first reported a position in Relay Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Rafferty Asset Management's Relay Therapeutics position peaked at $7.88M in Q2 2023.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.